Page 1,680«..1020..1,6791,6801,6811,682..1,6901,700..»

Scientists coax stem cells to form 3-D mini lungs …

Posted: August 11, 2016 at 6:49 am

ANN ARBOR, Mich. -- Scientists have coaxed stem cells to grow the first three-dimensional mini lungs.

Previous research has focused on deriving lung tissue from flat cell systems or growing cells onto scaffolds made from donated organs.

In a study published in the online journal eLife the multi-institution team defined the system for generating the self-organizing human lung organoids, 3-D structures that mimic the structure and complexity of human lungs.

These mini lungs can mimic the responses of real tissues and will be a good model to study how organs form, change with disease, and how they might respond to new drugs, says senior study author Jason R. Spence, Ph.D., assistant professor of internal medicine and cell and developmental biology at the University of Michigan Medical School.

The scientists succeeded in growing structures resembling both the large airways known as bronchi and small lung sacs called alveoli.

Since the mini lung structures were developed in a dish, they lack several components of the human lung, including blood vessels, which are a critical component of gas exchange during breathing.

Still, the organoids may serve as a discovery tool for researchers as they churn basic science ideas into clinical innovations. A practical solution lies in using the 3-D structures as a next step from, or complement to, animal research.

Cell behavior has traditionally been studied in the lab in 2-D situations where cells are grown in thin layers on cell-culture dishes. But most cells in the body exist in a three-dimensional environment as part of complex tissues and organs.

Researchers have been attempting to re-create these environments in the lab, successfully generating organoids that serve as models of the stomach, brain, liver and human intestine.

The advantage of growing 3-D structures of lung tissue, Spence says, is that their organization bears greater similarity to the human lung.

The panel on the left is a cross section through an organoid, viewed through a microscope and stained to visualize the lung tissue. Lung tissue in organoids is organized in a similar manner to the adult lung, shown in the right panel.

To make these lung organoids, researchers at the U-Ms Spence Lab and colleagues from the University of California, San Francisco; Cincinnati Childrens Hospital Medical Center; Seattle Childrens Hospital and University of Washington, Seattle manipulated several of the signaling pathways that control the formation of organs.

First, stem cells the bodys master cells -- were instructed to form a type of tissue called endoderm, which is found in early embryos and gives rise to the lung, liver and several other internal organs.

Scientists activated two important development pathways that are known to make endoderm form three-dimensional tissue. By inhibiting two other key development pathways at the same time, the endoderm became tissue that resembles the early lung found in embryos.

In the lab, this early lung-like tissue spontaneously formed three-dimensional spherical structures as it developed. The next challenge was to make these structures expand and develop into lung tissue. To do this, the team exposed the cells to additional proteins that are involved in lung development.

The resulting lung organoids survived in the lab for over 100 days.

We expected different cells types to form, but their organization into structures resembling human airways was a very exciting result, says lead study author Briana Dye, a graduate student in the U-M Department of Cell and Developmental Biology.

The research has gained support from the National Heart, Lung and Blood Institute (NHLBI), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the March of Dimes and the U-Ms Center for Organogenesis and Biological Sciences Scholars Program (BSSP).

###

Reference: In vitro generation of human pluripotent stem cell derived lung organoids, eLife, DOI: http//dx.doi.org/10.7554/eLife.05098.001

Link:
Scientists coax stem cells to form 3-D mini lungs ...

Posted in Michigan Stem Cells | Comments Off on Scientists coax stem cells to form 3-D mini lungs …

Hawaii Stem Cell Treatment Center | Facebook

Posted: August 10, 2016 at 4:46 am

Educational Event Feb 10, 2016 Stem Cell Research and Treatment Lecture Call 808-945-5433 to RSVP

Learn the latest about Stem Cell Therapy that you may have read about or seen on the internet. What are the facts and the medical science on the stem cell treatments from Dr. Michael Pasquale, Board Certified Plastic Surgeon and founder of the Hawaii Stem Cell Treatment Center. This will be a true educational event open to the public to hear about the latest research, techniques and what is being done with stem cells across the globe.

Dr. Pasquale has just returned from Korea as Chairman for the First Annual Stem Cell Symposium with latest information from Asia, Europe and Mainland USA. The Hawaii Stem Cell Treatment Center was started in 2013 and is the only medically based Stem Cell Treatment Center in our state. It has been involved in research regarding diseases such as COPD, Arthritis , Athletic Injures and more. Come learn about the risk , pros and cons and various options available now and in the future , from one of the leading clinical experts in this new science.

Read the original here:
Hawaii Stem Cell Treatment Center | Facebook

Posted in Hawaii Stem Cells | Comments Off on Hawaii Stem Cell Treatment Center | Facebook

Journal home : Nature Biotechnology

Posted: August 10, 2016 at 4:44 am

Skip authors

Mingxun Wang, Jeremy J Carver, Vanessa V Phelan, Laura M Sanchez, Neha Garg, Yao Peng, Don Duy Nguyen, Jeramie Watrous, Clifford A Kapono, Tal Luzzatto-Knaan, Carla Porto, Amina Bouslimani, Alexey V Melnik, Michael J Meehan, Wei-Ting Liu, Max Crsemann, Paul D Boudreau, Eduardo Esquenazi, Mario Sandoval-Caldern, Roland D Kersten, Laura A Pace, Robert A Quinn, Katherine R Duncan, Cheng-Chih Hsu, Dimitrios J Floros, Ronnie G Gavilan, Karin Kleigrewe, Trent Northen, Rachel J Dutton, Delphine Parrot, Erin E Carlson, Bertrand Aigle, Charlotte F Michelsen, Lars Jelsbak, Christian Sohlenkamp, Pavel Pevzner, Anna Edlund, Jeffrey McLean, Jrn Piel, Brian T Murphy, Lena Gerwick, Chih-Chuang Liaw, Yu-Liang Yang, Hans-Ulrich Humpf, Maria Maansson, Robert A Keyzers, Amy C Sims, Andrew R Johnson, Ashley M Sidebottom, Brian E Sedio, Andreas Klitgaard, Charles B Larson, Cristopher A Boya P, Daniel Torres-Mendoza, David J Gonzalez, Denise B Silva, Lucas M Marques, Daniel P Demarque, Egle Pociute, Ellis C O'Neill, Enora Briand, Eric J N Helfrich, Eve A Granatosky, Evgenia Glukhov, Florian Ryffel, Hailey Houson, Hosein Mohimani, Jenan J Kharbush, Yi Zeng, Julia A Vorholt, Kenji L Kurita, Pep Charusanti, Kerry L McPhail, Kristian Fog Nielsen, Lisa Vuong, Maryam Elfeki, Matthew F Traxler, Niclas Engene, Nobuhiro Koyama, Oliver B Vining, Ralph Baric, Ricardo R Silva, Samantha J Mascuch, Sophie Tomasi, Stefan Jenkins, Venkat Macherla, Thomas Hoffman, Vinayak Agarwal, Philip G Williams, Jingqui Dai, Ram Neupane, Joshua Gurr, Andrs M C Rodrguez, Anne Lamsa, Chen Zhang, Kathleen Dorrestein, Brendan M Duggan, Jehad Almaliti, Pierre-Marie Allard, Prasad Phapale, Louis-Felix Nothias, Theodore Alexandrov, Marc Litaudon, Jean-Luc Wolfender, Jennifer E Kyle, Thomas O Metz, Tyler Peryea, Dac-Trung Nguyen, Danielle VanLeer, Paul Shinn, Ajit Jadhav, Rolf Mller, Katrina M Waters, Wenyuan Shi, Xueting Liu, Lixin Zhang, Rob Knight, Paul R Jensen, Bernhard Palsson, Kit Pogliano, Roger G Linington, Marcelino Gutirrez, Norberto P Lopes, William H Gerwick, Bradley S Moore, Pieter C Dorrestein & Nuno Bandeira

GNPS is an open-access community-curated analysis platform for sharing natural product mass spectrometry data that enables continuous, automatic reanalysis of deposited 'living' data sets.

Excerpt from:
Journal home : Nature Biotechnology

Posted in Biotechnology | Comments Off on Journal home : Nature Biotechnology

The 2012 Nobel Prize in Physiology or Medicine – Press Release

Posted: August 10, 2016 at 4:43 am

Press Release

2012-10-08

The Nobel Assembly at Karolinska Institutet has today decided to award

The Nobel Prize in Physiology or Medicine 2012

jointly to

John B. Gurdon and Shinya Yamanaka

for the discovery that mature cells can be reprogrammed to become pluripotent

The Nobel Prize recognizes two scientists who discovered that mature, specialised cells can be reprogrammed to become immature cells capable of developing into all tissues of the body. Their findings have revolutionised our understanding of how cells and organisms develop.

John B. Gurdon discovered in 1962 that the specialisation of cells is reversible. In a classic experiment, he replaced the immature cell nucleus in an egg cell of a frog with the nucleus from a mature intestinal cell. This modified egg cell developed into a normal tadpole. The DNA of the mature cell still had all the information needed to develop all cells in the frog.

Shinya Yamanaka discovered more than 40 years later, in 2006, how intact mature cells in mice could be reprogrammed to become immature stem cells. Surprisingly, by introducing only a few genes, he could reprogram mature cells to become pluripotent stem cells, i.e. immature cells that are able to develop into all types of cells in the body.

These groundbreaking discoveries have completely changed our view of the development and cellular specialisation. We now understand that the mature cell does not have to be confined forever to its specialised state. Textbooks have been rewritten and new research fields have been established. By reprogramming human cells, scientists have created new opportunities to study diseases and develop methods for diagnosis and therapy.

All of us developed from fertilized egg cells. During the first days after conception, the embryo consists of immature cells, each of which is capable of developing into all the cell types that form the adult organism. Such cells are called pluripotent stem cells. With further development of the embryo, these cells give rise to nerve cells, muscle cells, liver cells and all other cell types - each of them specialised to carry out a specific task in the adult body. This journey from immature to specialised cell was previously considered to be unidirectional. It was thought that the cell changes in such a way during maturation that it would no longer be possible for it to return to an immature, pluripotent stage.

John B. Gurdon challenged the dogma that the specialised cell is irreversibly committed to its fate. He hypothesised that its genome might still contain all the information needed to drive its development into all the different cell types of an organism. In 1962, he tested this hypothesis by replacing the cell nucleus of a frog's egg cell with a nucleus from a mature, specialised cell derived from the intestine of a tadpole. The egg developed into a fully functional, cloned tadpole and subsequent repeats of the experiment yielded adult frogs. The nucleus of the mature cell had not lost its capacity to drive development to a fully functional organism.

Gurdon's landmark discovery was initially met with scepticism but became accepted when it had been confirmed by other scientists. It initiated intense research and the technique was further developed, leading eventually to the cloning of mammals. Gurdon's research taught us that the nucleus of a mature, specialized cell can be returned to an immature, pluripotent state. But his experiment involved the removal of cell nuclei with pipettes followed by their introduction into other cells. Would it ever be possible to turn an intact cell back into a pluripotent stem cell?

Shinya Yamanaka was able to answer this question in a scientific breakthrough more than 40 years after Gurdons discovery. His research concerned embryonal stem cells, i.e. pluripotent stem cells that are isolated from the embryo and cultured in the laboratory. Such stem cells were initially isolated from mice by Martin Evans (Nobel Prize 2007) and Yamanaka tried to find the genes that kept them immature. When several of these genes had been identified, he tested whether any of them could reprogram mature cells to become pluripotent stem cells.

Yamanaka and his co-workers introduced these genes, in different combinations, into mature cells from connective tissue, fibroblasts, and examined the results under the microscope. They finally found a combination that worked, and the recipe was surprisingly simple. By introducing four genes together, they could reprogram their fibroblasts into immature stem cells!

The resulting induced pluripotent stem cells (iPS cells) could develop into mature cell types such as fibroblasts, nerve cells and gut cells. The discovery that intact, mature cells could be reprogrammed into pluripotent stem cells was published in 2006 and was immediately considered a major breakthrough.

The discoveries of Gurdon and Yamanaka have shown that specialised cells can turn back the developmental clock under certain circumstances. Although their genome undergoes modifications during development, these modifications are not irreversible. We have obtained a new view of the development of cells and organisms.

Research during recent years has shown that iPS cells can give rise to all the different cell types of the body. These discoveries have also provided new tools for scientists around the world and led to remarkable progress in many areas of medicine. iPS cells can also be prepared from human cells.

For instance, skin cells can be obtained from patients with various diseases, reprogrammed, and examined in the laboratory to determine how they differ from cells of healthy individuals. Such cells constitute invaluable tools for understanding disease mechanisms and so provide new opportunities to develop medical therapies.

Sir John B. Gurdon was born in 1933 in Dippenhall, UK. He received his Doctorate from the University of Oxford in 1960 and was a postdoctoral fellow at California Institute of Technology. He joined Cambridge University, UK, in 1972 and has served as Professor of Cell Biology and Master of Magdalene College. Gurdon is currently at the Gurdon Institute in Cambridge.

Shinya Yamanaka was born in Osaka, Japan in 1962. He obtained his MD in 1987 at Kobe University and trained as an orthopaedic surgeon before switching to basic research. Yamanaka received his PhD at Osaka City University in 1993, after which he worked at the Gladstone Institutes in San Francisco, USA and Nara Institute of Science and Technology in Japan. Yamanaka is currently Professor at Kyoto University, where he directs its Center for iPS Research and Application. He is also a senior investigator at the Gladstone Institutes.

Gurdon, J.B. (1962). The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. Journal of Embryology and Experimental Morphology 10:622-640.

Takahashi, K., Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676.

High resolution image (pdf 670 Kb)

The Nobel Assembly, consisting of 50 professors at Karolinska Institutet, awards the Nobel Prize in Physiology or Medicine. Its Nobel Committee evaluates the nominations. Since 1901 the Nobel Prize has been awarded to scientists who have made the most important discoveries for the benefit of mankind.

Nobel Prize is the registered trademark of the Nobel Foundation

To cite this page MLA style: "The 2012 Nobel Prize in Physiology or Medicine - Press Release". Nobelprize.org. Nobel Media AB 2014. Web. 10 Aug 2016. <http://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/press.html>

Continued here:
The 2012 Nobel Prize in Physiology or Medicine - Press Release

Posted in Cell Medicine | Comments Off on The 2012 Nobel Prize in Physiology or Medicine – Press Release

Molecular & Cellular Medicine

Posted: August 9, 2016 at 1:42 pm

Home Molecular & Cellular Medicine Menu

Research in the Molecular and Cellular Medicine department spans a wide range of biological processes, from structure and function of biomolecules to cell physiology. Emphasis is placed on understanding normal and abnormal biological function at the molecular and cellular levels. Using state-of-the-art biophysical technologies, research programs at the molecular level focus on understanding how proteins are synthesized, folded, assembled into functional macromolecules and trafficked throughout the cell. Reverse genetic approaches are used to elucidate the roles of newly discovered proteins and define functional protein domains. Research programs that bridge molecular and cellular levels focus on understanding mechanisms of basic cellular physiology (DNA replication, transcription, translation and protein sorting), molecules that control complex regulatory pathways (signal transduction, gene regulation, epigenetics, development and differentiation) and the molecular basis for cancer. Many faculty members have strong collaborative ties with Texas A&M University research groups in the Chemistry and Biochemistry/Biophysics departments or belong to multi-disciplinary research groups affiliated with Texas A&M University, including programs in Genetics, Neurosciences and Virology.

440 Reynolds Medical Building College Station, TX 77843-1114 Phone: (979) 436-0856 Fax: (979) 847-9481 Toll Free: (800) 298-2260 (U.S. only)

Last edited by: chauhan 07/27/2016

See the rest here:
Molecular & Cellular Medicine

Posted in Cell Medicine | Comments Off on Molecular & Cellular Medicine

Cell Therapy Institute – Nova Southeastern University NSU

Posted: August 9, 2016 at 1:42 pm

An International Biomedical Research Alliance Committed to Curing Disease

Nova Southeastern University (NSU) is at the forefront of conducting pioneering biomedical research with the launch of its soon-to-be-completed, 215,000 sq. ft. Center for Collaborative Research (CCR), one of the largest and most advanced research facilities in Florida with state-of-the-art laboratories. The CCR will be home to a diverse group of accomplished physician-scientists and basic science researchers, representing many interdisciplinary sciences. As part of its bold new research mission, the university has launched the NSU Cell Therapy Institute, a unique collaboration with leading medical research scientists from Swedens world-renowned Karolinska Institutet (KI). KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine annually.

Mission:The NSU Cell Therapy Institute is dedicated to the discovery and development of innovative translational biomedical research, focused on the potential of cell-based therapies to prevent, treat and cure life-threatening and debilitating diseases. The Institute is accelerating the advancement of next-generation approaches to precision medicine such as targeted immunotherapy and regenerative medicine with an initial focus on treating cancers, heart disease and disorders causing blindness. The Institute is prioritizing establishing collaborations with other world-class universities, hospitals, research institutions and corporate partners.

With an overriding mission to contribute to the improvement of human health through research and education, Karolinska Institutet provides more than 40% of the medical academic research conducted in Sweden and offers the country s broadest range of education in medicine and health sciences. Many of the discoveries made at Karolinska Institutet have been of great significance, including the pacemaker, the gamma knife, the sedimentation reaction, the Seldinger technique and the preparation of chemically pure insulin. Since 1901, the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine.

Research Team: Evren Alici, M.D., Ph.D.; Adil Duru, Ph.D.; Carin Dahlberg, Ph.D. Summary: Natural killer cells (NK-cells) are cytotoxic lymphocytes critical to the innate immune system. Discovered at Karolinska Institutet in 1974, NK-cells hold the potential to be programmed to selectively bind to and destroy tumor cells with very few side-effects. Preliminary human studies are encouraging in targeting multiple myeloma, a deadly form of blood cancer. New studies will be advanced at the NSU Cell Therapy Institute, including investigating novel approaches harnessing the potency of NK-cells against a broad range of difficult-to-treat cancers.

Research Team: Andreas Lundqvist, Ph.D.; Shannon Murray, Ph.D. Summary: Cancer can employ multiple defense mechanisms to suppress the immune system and avoid detection. For example, myeloid-derived suppressor cells (MDSC) can be used by cancer cells to down-regulate the immune system and diminish the cancer killing capabilities of T-cells, NK-cells, dendritic cells, macrophages and other immune responses. The NSU Cell Therapy Institute is advancing novel anti-MDSC approaches to overcome suppression defenses while recruiting targeted immune responses by both NK-cells and T-cells, as potential monotherapy or in combination with other anti-cancer treatments for malignant melanoma and kidney cancer.

Research Team: Richard Jove, Ph.D.; Thomas Temple, M.D. Summary: While standard cancer therapies such as chemotherapy and radiation can destroy many kinds of cancers, cancer stem cells possess the ability to escape, survive and metastasize to distant sites in the body. These cells typically develop into new tumors, destroy normal tissues such as bone and are often resistant to most therapies. The NSU Cell Therapy Institute is advancing novel approaches to modulating signaling pathways, such as JAK/STAT, which are critical to cancer stem cell survival and regeneration of normal tissue. By inhibiting cancer stem cell pathways, cancer recurrence may be eliminated, resulting in durable remissions. Conversely, activating these same pathways can enhance regeneration of damaged normal tissues including bone.

Research Team: Karl-Henrik Grinnemo, M.D., Ph.D.; Vladimir Beljanski, Ph.D. Summary: There are currently no available options to repair vital heart muscle and tissue following a heart attack, and heart transplantation is a highly limited option. The NSU Cell Therapy Institute is developing novel culturing systems to produce pure populations of mesenchymal stromal cells (MSCs) and at the same time activate cardiac progenitor cell differentiation. These activated cardiac MSCs can be differentiated into three types of cardiac cells: cardiomyocytes; endothelial cells; and smooth muscle cells. The ability of these cells to regenerate the damaged myocardium, while at the same time possessing traits that prevent immune rejection and inflammatory response, makes this a highly promising approach to restoring healthy heart function.

Research Team: Cecilia Osterholm Corbascio, PhD; Vladimir Beljanski, Ph.D. Summary: Valvular heart disease (VHD) is a major cause of death and disability worldwide, yet the mechanisms of this process remain largely unknown. Furthermore, the properties of currently used bioprosthetic valves lead to valve degeneration and subsequent heart failure. A regenerative approach would allow for the generation of new heart valves by combining the patients own stem cells with a biological matrix not prone to immunologically mediated deterioration. The focus of this research at NSU will be to study valvular heart disease from decoding mechanistic pathways to creating new valves from the patients own stem cells.

Research Team: Outi Hovata, M.D., Ph.D.; Ben Josey, Ph.D.Summary: Macular Degeneration (MD - dry & wet forms) is the leading cause of vision loss in Americans aged 60 or older. The dry form of the disease affects 90-95% of sufferers and causes vision loss in the center of a patients field of vision due to deterioration of the macula which is in the center of the retina. The NSU Cell Therapy Institute is developing a novel approach to cure dry MD by transplanting human stem cell-derived retinal pigment epithelial cell (RPE cells). This approach targets dry MD by replacing the degenerating, damaged cells in the eye with healthy RPE cells to restore full function and vision. Immune rejection has been a major impediment in such transplant techniques, so this program is developing differentiated RPE cells combined with technology that induces transplant tolerance, eliminating the need for chronic immunosuppression.

The NSU Cell Therapy Institute offers cutting-edge molecular and cellular profiling analyses to support its research programs, and those of its collaborative partners, with the highest quality of comprehensive scientific resources, facilities and staff, including in the areas of:

Philanthropy, sponsored research and other key collaborative partnerships play a critical role in the NSU Cell Therapy Institutes mission to impact the understanding, prevention, and treatment of a broad range of life-threatening and debilitating diseases. The NSU Cell Therapy Institute offers many kinds of sponsorship and partnering options for individual donors, foundations, and corporations in order to accelerate next-generation cures to patients in urgent need.

For more information about the NSU Cell Therapy Institute, please contact:

Douglas W. Calder Director of Development & Strategic Planning NSU Cell Therapy Institute 3301 College Avenue Ft. Lauderdale, FL 33314 Phone: (954) 262-3382 Mobile: (772) 418-6302 Email: dcalder@nova.edu

Excerpt from:
Cell Therapy Institute - Nova Southeastern University NSU

Posted in Cell Therapy | Comments Off on Cell Therapy Institute – Nova Southeastern University NSU

National Human Genome Research Institute

Posted: August 8, 2016 at 5:47 am

How much does it cost to sequence a genome? A question often posed to NHGRI staff is "How much does it cost to sequence a human genome?" This is a timely question, as human genome sequencing is expanding from research tool to major clinical diagnostic test. To help everyone understand the cost, NHGRI recently developed a summary and infographic called The Cost of Sequencing a Human Genome to clarify how the cost of generating a human genome sequence is calculated. Read the summary | Read the infographic Gut bacteria co-evolved with animal hosts, offers human evolution clues Based on the DNA sequence of a moderately conserved gene in all bacteria, researchers have found that bacterial strains diverged and began to evolve separately in the guts of humans and chimpanzees 5 million years ago, and in humans and gorillas 15 million years ago. These dates are similar to when humans and apes evolved into a new species. It may now be possible to determine if this mutually beneficial relationship between gut bacteria and their animal hosts contributed to the formation of a new species. A perspective on the research from NHGRI Senior Investigator Julie Segre, Ph.D., appeared in the July 22 issue of Science. Read the perspective | Read the study Researchers advance treatment possibilities for Gaucher, Parkinson's National Institutes of Health researchers have identified and tested a molecule that shows promise as a possible treatment for the rare Gaucher disease and the more common Parkinson's disease. These findings demonstrate how insights from a rare disorder can have direct relevance to the treatment of more common disorders. Gaucher disease affects an estimated 1 in 50,000 to 1 in 100,000 people in the general population. Parkinson's disease affects more than 1 million people in North America and 7-10 million people worldwide. The findings were published July 12 in The Journal of Neuroscience. Read more Progeria cure remains elusive but new therapeutic options are emerging Development of a cure for Hutchinson-Gilford progeria syndrome (HGPS), a rare disease that causes rapid aging in children, remains elusive, NIH Director Francis Collins, M.D., Ph.D., wrote in a July 12 editorial in Circulation. But therapeutic options are emerging, and there is momentum in the basic and clinical research communities. His comments appeared in the same issue as findings of a new clinical trial that combines three drugs for the treatment of HGPS. Read Dr. Collins' editorial Read about the clinical trial Media Availability Genetics of type 2 diabetes revealed in unprecedented detail A comprehensive investigation of the underlying genetic architecture of type 2 diabetes has unveiled the most detailed look at the genetic differences that increase a person's risk for disease development. The findings, published July 11 in the journal Nature, reveal the complexity of the disease in more detail than previously appreciated and also identify several promising targets for new treatments. Read more

Excerpt from:
National Human Genome Research Institute

Posted in Human Genetics | Comments Off on National Human Genome Research Institute

Hormone replacement therapy (HRT) – NHS Choices

Posted: August 8, 2016 at 5:47 am

Hormone replacement therapy (HRT) is a treatment usedto relieve symptoms of themenopause. It replaces hormones that are at a lower level as you approach themenopause.

This page covers:

Benefits of HRT

How to get started

Who can take it

Types of HRT

Stopping HRT

Risks and side effects

Alternatives

The main benefit of HRT is that it can help relieve most of the menopausal symptoms, such as:

Many of these symptoms pass in a few years, but they canbe very unpleasant and taking HRT can offer relief for many women.

Itcan also help prevent weakening of the bones (osteoporosis), which is more common after the menopause.

Speak to your GP if you're interested in starting HRT.

You can normally begin HRT as soon asyou start experiencing menopausal symptoms and won't usually need to have any tests first.

Your GP can explain thedifferent types of HRTavailable and help you choose one that's suitable for you.

You'll usually be started off on a low dose, which can be increased at a later stage. It may take a few weeks to feel the effects of treatment and there may be someside effects at first.

Your GP will normally recommend trying treatment for three months to see if it helps. If it doesn't, they may suggest changing your dose or changing the type of HRT you're taking.

Most women can have HRT if they're experiencing symptoms associated with the menopause.

ButHRT may not be suitable if you:

Inthese circumstances,alternatives to HRTmay be recommended instead.

There are many different types of HRT and finding the right one for you can be tricky.

There are different:

Your GP can give you advice to help you choose which type is best for you.You may need to try more than one type before you find one that works best.

Read more about the different types ofHRT.

There's no limit on how long you can take HRT, but talk to your GP about the duration of treatment they recommend.

Most womenstop takingitonce their menopausal symptoms pass, which is usually after a few years.

When you decide to stop, you can choose to do so suddenly or gradually.

Gradually decreasing your HRT dose is usually recommended because it's less likely to cause your symptoms to come back in the short term.

Contact your GP if you have symptoms that persist for several months after you stop HRT, or if you have particularly severe symptoms. You may need to start HRT again.

As with any medication, HRT can cause side effects. But these will usually pass within three months of starting treatment.

Common side effects include:

Some types of HRT can also cause a small increase in your risk of certain serious problems, such asblood clots and breast cancer.

The benefits of HRT are generally felt to outweigh the risks. But speak to your GP if you have any concerns about taking HRT.

Read more aboutside effects of HRTandrisks of HRT.

If you're unable totake HRT or decide not to,you may want to consider alternativeways of controlling your menopausal symptoms.

Alternatives to HRT include:

Several remedies (such as bioidenticalhormones) are claimed to help withmenopausal symptoms, but these aren't recommended because it's not clear how safe and effective they are.

Read more about alternatives to HRT.

Page last reviewed: 20/07/2016

Next review due: 20/07/2019

Here is the original post:
Hormone replacement therapy (HRT) - NHS Choices

Posted in Hormone Replacement Therapy | Comments Off on Hormone replacement therapy (HRT) – NHS Choices

Estrogen and Progestin (Hormone Replacement Therapy): MedlinePlus Drug …

Posted: August 8, 2016 at 5:47 am

Keep all appointments with your doctor and the laboratory. You should have a complete physical exam, including blood pressure measurements, breast and pelvic exams, and a Pap test at least yearly. Follow your doctor's directions for examining your breasts; report any lumps immediately.

If you are taking hormone replacement therapy to treat symptoms of menopause, your doctor will check every 3 to 6 months to see if you still need this medication. If you are taking this medication to prevent thinning of the bones (osteoporosis), you will take it for a longer period of time.

Before you have any laboratory tests, tell the laboratory personnel that you take hormone replacement therapy, because this medication may interfere with some laboratory tests.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Read more from the original source:
Estrogen and Progestin (Hormone Replacement Therapy): MedlinePlus Drug ...

Posted in Hormone Replacement Therapy | Comments Off on Estrogen and Progestin (Hormone Replacement Therapy): MedlinePlus Drug …

HCG Diet Injections Mixing Instructions – Nu Image Medical

Posted: August 8, 2016 at 5:47 am

Originally posted here:
HCG Diet Injections Mixing Instructions - Nu Image Medical

Posted in HCG Diet | Comments Off on HCG Diet Injections Mixing Instructions – Nu Image Medical

Page 1,680«..1020..1,6791,6801,6811,682..1,6901,700..»